CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 170 filers reported holding CLOVIS ONCOLOGY INC in Q4 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $45,970 | -29.8% | 16,963 | +15.6% | 0.00% | 0.0% |
Q3 2021 | $65,464 | -56.2% | 14,678 | -43.1% | 0.00% | -50.0% |
Q2 2021 | $149,576 | -9.9% | 25,789 | +9.1% | 0.00% | 0.0% |
Q1 2021 | $165,995 | +32.5% | 23,646 | -9.4% | 0.00% | 0.0% |
Q4 2020 | $125,266 | -15.7% | 26,097 | +2.4% | 0.00% | -33.3% |
Q3 2020 | $148,543 | -6.2% | 25,479 | +8.6% | 0.00% | 0.0% |
Q2 2020 | $158,369 | +60.1% | 23,462 | +50.9% | 0.00% | +50.0% |
Q1 2020 | $98,898 | -39.0% | 15,550 | 0.0% | 0.00% | -33.3% |
Q4 2019 | $162,109 | +165.9% | 15,550 | +0.2% | 0.00% | +200.0% |
Q3 2019 | $60,966 | -73.6% | 15,513 | 0.0% | 0.00% | -75.0% |
Q2 2019 | $230,678 | -40.1% | 15,513 | 0.0% | 0.00% | -42.9% |
Q1 2019 | $385,033 | +38.2% | 15,513 | 0.0% | 0.01% | +16.7% |
Q4 2018 | $278,613 | -38.8% | 15,513 | 0.0% | 0.01% | -25.0% |
Q3 2018 | $455,617 | -99.9% | 15,513 | 0.0% | 0.01% | -27.3% |
Q2 2018 | $705,377,000 | -6.8% | 15,513 | +8.2% | 0.01% | 0.0% |
Q1 2018 | $757,099,000 | +78682.4% | 14,339 | +1.4% | 0.01% | -15.4% |
Q4 2017 | $961,000 | -60.2% | 14,138 | -51.7% | 0.01% | -13.3% |
Q3 2017 | $2,414,000 | -12.0% | 29,294 | 0.0% | 0.02% | -21.1% |
Q2 2017 | $2,743,000 | +69.3% | 29,294 | +15.1% | 0.02% | +72.7% |
Q1 2017 | $1,620,000 | +54.7% | 25,449 | +8.0% | 0.01% | +37.5% |
Q4 2016 | $1,047,000 | +19.2% | 23,566 | -3.3% | 0.01% | +33.3% |
Q3 2016 | $878,000 | +166.1% | 24,364 | +1.3% | 0.01% | +200.0% |
Q2 2016 | $330,000 | -10.8% | 24,046 | +24.9% | 0.00% | -33.3% |
Q1 2016 | $370,000 | -45.1% | 19,251 | 0.0% | 0.00% | -40.0% |
Q4 2015 | $674,000 | -62.5% | 19,251 | -1.6% | 0.01% | -61.5% |
Q3 2015 | $1,799,000 | +12.5% | 19,559 | +7.5% | 0.01% | +18.2% |
Q2 2015 | $1,599,000 | +12.1% | 18,198 | -5.3% | 0.01% | +10.0% |
Q1 2015 | $1,426,000 | +32.5% | 19,208 | 0.0% | 0.01% | +42.9% |
Q4 2014 | $1,076,000 | +23.5% | 19,208 | 0.0% | 0.01% | +16.7% |
Q3 2014 | $871,000 | +9.6% | 19,208 | 0.0% | 0.01% | 0.0% |
Q2 2014 | $795,000 | -21.8% | 19,208 | +30.9% | 0.01% | -14.3% |
Q1 2014 | $1,016,000 | +14.9% | 14,671 | 0.0% | 0.01% | +16.7% |
Q4 2013 | $884,000 | +12.3% | 14,671 | +13.3% | 0.01% | 0.0% |
Q3 2013 | $787,000 | +7.5% | 12,949 | +18.5% | 0.01% | 0.0% |
Q2 2013 | $732,000 | – | 10,925 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |